Currently out of the existing stock ratings of Gregory Renza, 346 are a BUY (85.22%), 60 are a HOLD (14.78%).

Gregory Renza

Work Performance Price Targets & Ratings Chart

Analyst Gregory Renza, currently employed at TRUIST, carries an average stock price target met ratio of 47.44% that have a potential upside of 43.77% achieved within 168 days. Previously, Gregory Renza worked at RBC.

Gregory Renza’s has documented 780 price targets and ratings displayed on 47 stocks. The coverage is on Healthcare, Consumer Defensive sectors.

Most recent stock forecast was given on XNCR, Xencor.

Wall Street Analyst Gregory Renza

Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $111 was fulfilled within 1 day with a profit of $15.2 (15.87%) receiving and performance score of 158.66.

Average potential price target upside

ACAD ACADIA Pharmaceuticals APRE Aprea Therapeutics APTO Aptose Biosciences AVTX Avalo Therapeutics BLU BELLUS Health GMDA Gamida Cell Ltd INO Inovio Pharmaceuticals ITRM Iterum Therapeutics PLC MORF Morphic XNCR Xencor GBT Global Blood Therapeutics SGEN Seagen ADCT ADC Therapeutics SA RXDX Prometheus Biosciences VRCA Verrica Pharmaceuticals JAZZ Jazz Pharmaceuticals PLC AMGN Amgen IDYA Ideaya Biosciences LIFE aTyr Pharma NRIX Nurix Therapeutics NUVB Nuvation Bio PRVB Provention Bio SPRB Spruce Biosciences VIRX Viracta Therapeutics VSTM Verastem ARQL ArQule ALPN Alpine Immune Sciences CRMD CorMedix EXEL Exelixis PCRX Pacira Pharmaceuticals VRDN Viridian Therapeutics AGIO Agios Pharm BCYC Bicycle Therapeutics Ltd FULC Fulcrum Therapeutics FUSN Fusion Pharmaceuticals JSPR Jasper Therapeutics CATX Perspective Therapeutics CGON CG Oncology, Common stock CDTX Cidara Therapeutics GILD Gilead Sciences MNKD MannKind Corp REGN Regeneron Pharmaceuticals PR Permian Resources MO Altria Group ABVX Abivax SA American Depositary Shares RVMD Revolution Medicines ZYME Zymeworks Common Stock

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 14-Dec-2025

$33

$12.32 (59.57%)

$37

6 days ago
(24-Sep-2026)

0/3 (0%)

$12.32 (59.57%)

Buy Since 16-Apr-2025

$34

$13.32 (64.41%)

$36

6 days ago
(24-Sep-2026)

4/6 (66.67%)

$13.32 (64.41%)

144

Buy Since 25-Nov-2019

$33

$12.32 (59.57%)

$36

6 days ago
(24-Sep-2026)

9/25 (36%)

$12.32 (59.57%)

238

Buy Since 24-Sep-2025

$31

$10.32 (49.90%)

$38

6 days ago
(24-Sep-2026)

2/6 (33.33%)

$10.32 (49.90%)

574

Buy Since 27-Feb-2024

$35

$14.32 (69.25%)

$41

6 days ago
(24-Sep-2026)

9/15 (60%)

$14.32 (69.25%)

393

Show more analysts

Please expand the browser size to see the chart

Which stock is Gregory Renza most bullish on?

Potential upside of $59.94 has been obtained for ABVX (ABIVAX SA AMERICAN DEPOSITARY SHARES)

Which stock is Gregory Renza most reserved on?

Potential downside of -$52.61 has been obtained for AMGN (AMGEN)

What Year was the first public recommendation made by Gregory Renza?

On 2017
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?